Display options
Cite
Pelleg A, Kutalek SP, Flammang D, et al. ATPace™: injectable adenosine 5'-triphosphate : Diagnostic and therapeutic indications. Purinergic Signal. 2011;8:57-60doi: 10.1007/s11302-011-9268-1.
Pelleg, A., Kutalek, S. P., Flammang, D., & Benditt, D. (2012). ATPace™: injectable adenosine 5'-triphosphate : Diagnostic and therapeutic indications. Purinergic signalling, 857-60. https://doi.org/10.1007/s11302-011-9268-1
Pelleg, Amir, et al. "ATPace™: injectable adenosine 5'-triphosphate : Diagnostic and therapeutic indications." Purinergic signalling vol. 8 (2012): 57-60. doi: https://doi.org/10.1007/s11302-011-9268-1
Pelleg A, Kutalek SP, Flammang D, Benditt D. ATPace™: injectable adenosine 5'-triphosphate : Diagnostic and therapeutic indications. Purinergic Signal. 2012 Feb;8:57-60. doi: 10.1007/s11302-011-9268-1. Epub 2011 Nov 06. PMID: 22057692; PMCID: PMC3265710.
Copy Download .nbib Format: NLM
Share it on

Purinergic Signal. 2012 Feb;8:57-60. doi: 10.1007/s11302-011-9268-1. Epub 2011 Nov 06.

ATPace™: injectable adenosine 5'-triphosphate : Diagnostic and therapeutic indications.

Purinergic signalling

Amir Pelleg, Steven P Kutalek, Daniel Flammang, David Benditt

Affiliations

  1. Division of Cardiology, Department of Medicine, Drexel University College of Medicine, 245 N 15th Street, NCB, MS#470, Philadelphia, PA, 19102-1192, USA, [email protected].

PMID: 22057692 PMCID: PMC3265710 DOI: 10.1007/s11302-011-9268-1

Abstract

ATPace™, a novel injectable formulation of adenosine 5'-triphosphate (ATP), is developed by Cordex Pharma, Inc. (Cordex) as a diagnostic and therapeutic drug for the management of cardiac bradyarrhythmias. Extracellular ATP exerts multiple effects in various cell types by activating cell-surface receptors known as P2 receptors. In the heart, ATP suppresses the automaticity of cardiac pacemakers and atrioventricular (AV) nodal conduction via adenosine, the product of its degradation by ecto-enzymes, as well as by triggering a cardio-cardiac vagal reflex. ATP, given as a rapid intravenous bolus injection, has been used since the late 1940s as a highly effective and safe therapeutic agent for the acute termination of reentrant paroxysmal supraventricular tachycardia (PSVT) involving the AV node. In addition, preliminary studies have shown that ATP can also be used as a diagnostic agent for the identification of several cardiac disorders including sinus node dysfunction (sick sinus syndrome), dual AV nodal pathways, long QT syndrome, and bradycardic syncope. The US Food and Drug Administration has approved Cordex formulation for ATP as an Investigational New Drug and two pathways for its marketing approval; one therapeutic, i.e., acute termination of paroxysmal PSVT, and the other diagnostic, i.e., the identification of patients with bradycardic syncope who can benefit from pacemaker therapy. The scientific rationale for the development of ATPace™ is discussed.

References

  1. J Cardiovasc Pharmacol. 2010 Jul;56(1):106-9 - PubMed
  2. Am J Cardiol. 1985 Feb 15;55(5):571-6 - PubMed
  3. J Am Coll Cardiol. 2003 Jan 1;41(1):93-8 - PubMed
  4. J Electrocardiol. 2004 Oct;37(4):305-9 - PubMed
  5. Arzneimittelforschung. 1993 Dec;43(12):1313-6 - PubMed
  6. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):299-309 - PubMed
  7. Pacing Clin Electrophysiol. 1994 Nov;17(11 Pt 2):2211-6 - PubMed
  8. Circ Res. 1982 Nov;51(5):569-79 - PubMed
  9. Am J Physiol Regul Integr Comp Physiol. 2005 Mar;288(3):R651-5 - PubMed
  10. Am Heart J. 1990 Jul;120(1):180-8 - PubMed
  11. Europace. 1999 Apr;1(2):140-5 - PubMed
  12. Circulation. 1997 Aug 19;96(4):1201-8 - PubMed
  13. Am J Cardiol. 1997 Jun 19;79(12A):11-4 - PubMed
  14. Eur Heart J. 2006 Sep;27(18):2232-9 - PubMed
  15. Acta Physiol (Oxf). 2010 Jun;199(2):93-147 - PubMed
  16. Eur Heart J. 1984 May;5(5):394-403 - PubMed
  17. Heart Lung Circ. 2007 Jun;16(3):222-8 - PubMed
  18. Cell Mol Life Sci. 2007 Jun;64(12):1471-83 - PubMed
  19. Int J Cardiol. 2010 Nov 5;145(1):53-5 - PubMed
  20. Circulation. 1997 Dec 2;96(11):3921-7 - PubMed
  21. Europace. 2003 Oct;5(4):425-8 - PubMed
  22. Eur Heart J. 2006 Feb;27(4):469-75 - PubMed
  23. Physiol Rev. 2001 Apr;81(2):767-806 - PubMed
  24. J Cardiovasc Electrophysiol. 2005 Dec;16(12):1388-9 - PubMed
  25. Arch Mal Coeur Vaiss. 2002 Apr;95 Spec No 5:57-63 - PubMed
  26. Rev Physiol Biochem Pharmacol. 1975;72:55-81 - PubMed

Publication Types